Temodal (TMZ) in Concomitant Radiochemotherapy Followed by Sequential TMZ Chemotherapy in Newly Diagnosed Glioblastoma Multiforme Patients - an Observational Program
N/A
N/A
N/A
N/A
N/A
Not Enrolling
Both
Glioblastoma
Both
Glioblastoma
Trial Information
Temodal (TMZ) in Concomitant Radiochemotherapy Followed by Sequential TMZ Chemotherapy in Newly Diagnosed Glioblastoma Multiforme Patients - an Observational Program
Participant sampling method: consecutive patient sampling.
Inclusion Criteria:
- Newly diagnosed Glioblastoma multiforme
Exclusion Criteria:
- History of hypersensitivity to temozolomide or its components, or to dacarbazine.
- Women who are pregnant or breast-feeding.
- Patients with severe myelosuppression.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Safety: Number of Adverse Events in the Indicated Categories
Outcome Time Frame:
Weekly during the concomitant treatment phase, and then monthly during the monotherapy phase
Safety Issue:
Yes
Authority:
Austria: No Health Authority approval required according to local law.
Study ID:
P04816
NCT ID:
NCT00725010
Start Date:
April 2007
Completion Date:
April 2009
Related Keywords:
- Glioblastoma
- Glioblastoma
Name | Location |
|---|
